In the News
Tirzepatide may improve glycemic control when added to insulin glargine in type 2 diabetes
An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once weekly versus placebo.
Nearly one-third of patients were nonadherent to newly prescribed SGLT-2 inhibitors, GLP-1 receptor agonists
Factors associated with not filling a new prescription for a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist included older age, Black race, male sex, certain comorbid conditions, and having a primary care clinician prescribe the drug, a study found.
Obesity increasing in type 1 diabetes, associated with higher risk for chronic kidney disease
Obesity in type 1 diabetes rose from 2004 to 2018, and patients with type 1 had a higher adjusted prevalence of low estimated glomerular filtration rate and albuminuria than those with type 2, an analysis of one health system found.
MKSAP quiz: Medication choice for type 2 diabetes
This month's quiz asks readers to choose a second-line therapy for a 46-year-old woman with type 2 diabetes diagnosed three months ago. Her latest hemoglobin A1c value was 8.5%.
Spotlight on the gut microbiome
A Finnish study found that certain gut bacteria were more common in people who later developed type 2 diabetes, while an Israeli study identified a distinct microbial signature in adults with type 1 diabetes compared with healthy controls.
Insulin recalled due to potential missing label
Mylan Pharmaceuticals Inc. is recalling one batch of insulin glargine injection due to the potential for a missing label on some pens within a labeled carton.